Abstract
Effective delivery still remains a major hurdle in the development of gene based therapies. While technological advances have occurred that have improved delivery in general, there is still a need for controlled delivery in order to achieve therapeutic effects. Gene electrotransfer (GET) can be utilized to accomplish this. Careful selection of parameters used for delivery such as amplitude, duration and number of pulses as well as plasmid construct can be manipulated in order to achieve appropriate levels of local expression. Previously we have shown that direct delivery of the therapeutic cytokine, interleukin 12 (IL-12), to tumors using electrotransfer can generate local and systemic anti-tumor effects in pre-clinical and clinical studies. Using this model we hypothesized that modulating local gene expression using GET can affect therapeutic outcome. To test this, we used multiple GET protocols and plasmids to achieve varying levels of local IL-12 expression. We found that high local gene expression did not give rise to a better therapeutic outcome. This suggests the level and possibly the duration of gene expression are important in mediating the host immune response against melanoma. These data also emphasize the importance of considering the desired immune outcome of the therapy when selecting parameters for GET.
Keywords: Cytokine, electrotransfer, gene therapy, immunotherapy, interleukin-12, melanoma.
Current Gene Therapy
Title:Controlled Gene Delivery Can Enhance Therapeutic Outcome for Cancer Immune Therapy for Melanoma
Volume: 15 Issue: 1
Author(s): Shawna A. Shirley, Cathryn G. Lundberg, Fanying Li, Niculina Burcus and Richard Heller
Affiliation:
Keywords: Cytokine, electrotransfer, gene therapy, immunotherapy, interleukin-12, melanoma.
Abstract: Effective delivery still remains a major hurdle in the development of gene based therapies. While technological advances have occurred that have improved delivery in general, there is still a need for controlled delivery in order to achieve therapeutic effects. Gene electrotransfer (GET) can be utilized to accomplish this. Careful selection of parameters used for delivery such as amplitude, duration and number of pulses as well as plasmid construct can be manipulated in order to achieve appropriate levels of local expression. Previously we have shown that direct delivery of the therapeutic cytokine, interleukin 12 (IL-12), to tumors using electrotransfer can generate local and systemic anti-tumor effects in pre-clinical and clinical studies. Using this model we hypothesized that modulating local gene expression using GET can affect therapeutic outcome. To test this, we used multiple GET protocols and plasmids to achieve varying levels of local IL-12 expression. We found that high local gene expression did not give rise to a better therapeutic outcome. This suggests the level and possibly the duration of gene expression are important in mediating the host immune response against melanoma. These data also emphasize the importance of considering the desired immune outcome of the therapy when selecting parameters for GET.
Export Options
About this article
Cite this article as:
Shirley A. Shawna, Lundberg G. Cathryn, Li Fanying, Burcus Niculina and Heller Richard, Controlled Gene Delivery Can Enhance Therapeutic Outcome for Cancer Immune Therapy for Melanoma, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141121111630
DOI https://dx.doi.org/10.2174/1566523214666141121111630 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine-Lowering Treatment in Coronary Heart Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Activation of Latent HIV-1 Expression by Protein Kinase C Agonists. A Novel Therapeutic Approach to Eradicate HIV-1 Reservoirs
Current Drug Targets Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Analysis of Organic Components Released from Dental Resin Composites in Saliva and Other Biological Fluids Using Chromatographic Techniques
Current Organic Chemistry Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Mutant B-Raf Kinase Inhibitors as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Inhibitory Effect of Sesamolin on Melanogenesis in B16F10 Cells Determined by In Vitro and Molecular Docking Analyses
Current Pharmaceutical Biotechnology Prospects of Gene Therapy for Pulmonary Diseases: Progress and Limitations
Medicinal Chemistry Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Targeting Trail Towards the Clinic
Current Drug Targets Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Current Cancer Drug Targets Modulatory Effects and Molecular Mechanisms of Olive Oil and Other Dietary Lipids in Breast Cancer
Current Pharmaceutical Design Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies Application of NKT Cells in Immunotherapy
Current Immunology Reviews (Discontinued) Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design The Regulation of E3 Ubiquitin Ligases Cbl and its Cross-talking in Bone Homeostasis
Current Stem Cell Research & Therapy